Rhofade, Oxymetazoline Cream 1% for the redness of Rosacea
Rhofade is Allergan’s Oxymetazoline based topical treatment for the red face of rosacea. Rhofade is known chemically as a Selective α1-Adrenergic Receptor Agonist, and during the drug’s development was known as AGN-199201 and also V-101.
Recent Rosacea Blog Posts
In the coming months you will see more and more references to Rhofade. When a new rosacea treatment launches everyone wants to know what is it ? Asking this question makes sense as we normally only find out the name of a product right at the end of the development process. What we now know […]
One little pearl from the Allergan investor presentation is that the company is expecting Rhofade to be approved by the FDA in early 2017. Allergan Plc (AGN) Brenton L. Saunders on Q2 2016 Results – Earnings Call Transcript Aug. 8, 2016 2:03 PM ET About: Allergan plc (AGN) William J. Meury – Chief Commercial Officer […]
Allergan has confirmed that their Oxymetazoline based treatment due to be released in 2017 will be known as Rhofade. The brand name was confirmed in Allergan’s presentation to investors – Allergan plc Q2 2016 Earnings Presentation – Investor Relations, via the slide shown above. Business analysts are already commenting on their predictions for Rhofade’s success […]
In a document prepared for Allergan’s November 4, 2015 R&D Day presentation, Allergan is highlighting the development of its soon to be approved oxymetazoline 1% cream for rosacea. The slides relating to Oxymetazoline show the features of this product, along with other products in development, that Allergan wants to promote to investors. In the presentation […]
Rosacea sufferers learnt recently that Allergan’s Oxymetazoline based topical (likely to be called Azultro) has been submitted for FDA approval and could be approved in the first half of 2017. For those wanting to try this claimed gentler-than-Mirvaso treatment for a red face, waiting for another year can seem like an eternity. If you are […]
